title: Handling worker and third-party exposures to nanotherapeutics during clinical trials.
abstract: The article focuses on issues relating to occupational exposures of researchers and lab workers, and exposures of bystanders such as health care workers and family members during HSR using nanomaterials. Such third-party exposures give rise to unique challenges relating to oversight as well as exposures to worker groups not previously studied. Given the current state of knowledge regarding health risks from such exposures, a more precautionary approach to oversight seems advisable.
authors.affiliation: Division of Environmental Health Sciences, School of Public Health, University of Minnesota in Minneapolis, MN, USA.
authors.forename: Gurumurthy
authors.initials: G
authors.lastname: Ramachandran
authors.forename: John
authors.initials: J
authors.lastname: Howard
authors.forename: Andrew
authors.initials: A
authors.lastname: Maynard
authors.forename: Martin
authors.initials: M
authors.lastname: Philbert
mesh_terms: D002986:Clinical Trials as Topic / Q000941:ethics*; D004781:Environmental Exposure / Q000517:prevention & control; D006282:Health Personnel; D006801:Humans; D050997:Nanomedicine / Q000941:ethics*; D049329:Nanostructures / Q000009:adverse effects*; D009314:National Institute for Occupational Safety and Health, U.S.; D016273:Occupational Exposure / Q000517:prevention & control*; D012308:Risk Management / Q000331:legislation & jurisprudence / Q000379:methods; D014481:United States; D014489:United States Occupational Safety and Health Administration